Integrated Filing- Financial

Kilitch Drugs (India) Ltd. has announced a board meeting to review and approve its financial results for the quarter and nine months ended 31st December, 2024. The standalone unaudited financial results indicate net sales of ₹46.51 crore, marking a significant increase from ₹29.76 crore in the previous year.

The net profit after tax stands at ₹6.88 crore, up from ₹5.50 crore year-on-year.

The consolidated results also reflect strong growth, with total income reaching ₹57.89 crore.

This positive financial performance is likely to enhance investor sentiment, highlighting the company's operational resilience and growth trajectory in the pharmaceutical sector.